# To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis

> **NCT06061471** · PHASE2 · COMPLETED · sponsor: **Akeso** · enrollment: 454 (actual)

## Conditions studied

- Psoriasis
- Skin Diseases

## Interventions

- **DRUG:** AK111
- **DRUG:** AK111

## Key facts

- **NCT ID:** NCT06061471
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-22
- **Primary completion:** 2024-12-11
- **Final completion:** 2024-12-11
- **Target enrollment:** 454 (ACTUAL)
- **Last updated:** 2025-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06061471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06061471, "To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06061471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*